All In Biotech

Drug Trial Radar · NCT00255450

A Crossover Safety Study of Ferumoxytol Versus Placebo

A Double Blind, Placebo Controlled, Crossover Design, Multicenter Study of Intravenous Ferumoxytol Compared With Placebo

Last checked: Nov 20, 2026Latest source record: Nov 11, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 750 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

750

Actual

Start

Jan 2005

Primary completion

Not stated

Study completion Aug 2006

Sponsor

Lead sponsor
AMAG Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Nov 21, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This crossover safety study will evaluate the safety of a single dose of ferumoxytol compared to placebo in patients with chronic kidney disease.

Conditions

  • Anemia

Interventions

  • ferumoxytol or placeboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety evaluated by physical examinations, vital signs, laboratory tests and patient monitoring and evaluation.

Locations

41 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Mobile, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Mountain View, California

  • Site not named

    New Haven, Connecticut

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Ocala, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Augusta, Georgia

  • Site not named

    Newnan, Georgia

  • Site not named

    Peoria, Illinois

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Bethesda, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Detroit, Michigan

  • Site not named

    St Louis, Missouri

  • Site not named

    Broken Bow, Nebraska

  • Site not named

    Lebanon, New Hampshire

  • Site not named

    Flushing, New York

  • Site not named

    New York, New York

  • Site not named

    New York, New York

  • Site not named

    Orchard Park, New York

  • Site not named

    Raleigh, North Carolina

  • Site not named

    Columbus, Ohio

  • Site not named

    Portland, Oregon

  • Site not named

    Erie, Pennsylvania

  • Site not named

    Lancaster, Pennsylvania

  • Site not named

    Greenville, South Carolina

  • Site not named

    Sumter, South Carolina

  • Site not named

    Chattanooga, Tennessee

  • Site not named

    Knoxville, Tennessee

  • Site not named

    Austin, Texas

  • Site not named

    Houston, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Alexandria, Virginia

  • Site not named

    Charlottesville, Virginia

  • Site not named

    Chesapeake, Virginia

  • Site not named

    Norfolk, Virginia

  • Site not named

    Bluefield, West Virginia

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.